FdaApplication
BLA 761103
Identifiers
- fda_app_no: BLA761103
Properties
| Property | Value |
|---|---|
| applicant_name | Pfizer Ireland Pharmaceuticals Unlimited Company |
| application_type | BLA |
| approval_date | 2019-07-23 |
Revenue by product
RUXIENCE
| Period | Revenue |
|---|---|
| Q4 2023 | $88.0M |
| Q3 2023 | $88.0M |
| Q2 2023 | $100.0M |
| Q1 2023 | $114.0M |
| Q4 2022 | $101.0M |
| Q3 2022 | $120.0M |
| Q2 2022 | $113.0M |
| Q1 2022 | $124.0M |
| Q4 2021 | $148.0M |
| Q3 2021 | $124.0M |
| Q2 2021 | $120.0M |
| Q1 2021 | $98.0M |
| Q4 2020 | $92.0M |
| Q3 2020 | $59.0M |
| Q2 2020 | $11.0M |
| Q1 2020 | $7.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| RUXIENCE | RITUXIMAB-PVVR | 500MG/50ML (10MG/ML) | Injection |
| RUXIENCE | RITUXIMAB-PVVR | 100MG/10ML (10MG/ML) | Injection |
2 products